Tilray acquires UK medical cannabis clinic and digital pharmacy platform Lyphe Group

Tilray Brands

Tilray Brands

TLRY

0.00
  • Tilray completed acquisition of UK-based Lyphe Group, adding a medical cannabis clinic and digital pharmacy platform to its Tilray Medical business.
  • Lyphe Dispensary has dispensed about 150,000 units to date; Lyphe Clinic has treated more than 16,000 patients.
  • Deal expands Tilray Medical into a vertically integrated UK platform spanning clinical care, dispensing, and pharmaceutical distribution.
  • Transaction is expected to be accretive in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tilray Brands Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-014692), on April 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.